Amag supply interruptions for Makena could be problematic, says Piper

Piper Jaffray analyst Christopher Raymond noted that Amag Pharmaceuticals’ 10-Q that was released after the close on Friday included what he believes to be new risk language around supply for Makena’s 1mL, single use vial. While similar language was in place in the 10-K, Raymond said the situation appears to have worsened and he thinks this could be “problematic” for the franchise if not resolved soon. He maintains a Neutral rating on Amag shares.

https://bit.ly/2rrWVg2